(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 179.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Ac Immune Sa's revenue in 2026 is $4,746,153.On average, 6 Wall Street analysts forecast ACIU's revenue for 2026 to be $2,932,719,809, with the lowest ACIU revenue forecast at $323,133,326, and the highest ACIU revenue forecast at $9,614,640,830. On average, 5 Wall Street analysts forecast ACIU's revenue for 2027 to be $12,696,413,006, with the lowest ACIU revenue forecast at $8,046,386,081, and the highest ACIU revenue forecast at $20,565,157,152.
In 2028, ACIU is forecast to generate $8,125,439,794 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $18,256,625,931.